NovaRx Corporation is bio-pharamaceutical firm based on an innovative, award-winning anti-cancer vaccine technology. Many types of cancer cells produce a substance that effectively hides them from the body's natural immune defense system, allowing them to grow out of control. NovaRx is developing a vaccine that unmasks the cancer cells and exposes them to the body's immune system. This permits the immune system to destroy the cancer cells and to prevent the tumor from growing or spreading to other parts of the body. During 2014, the company's product Lucanix, a therapeutic vaccine for advanced non-small cell lung cancer, was in phase 3 clinical trials. Glionix, a therapeutic vaccine for certain brain tumors, was in phase 2 clinical trials. The following year - 2015 - NovaRx was acquired by Viropro a company specializing in cell line and biopharmaceutical process development
